Oslo, Norway, 4 August 2024 – Reference is made to the joint stock exchange announcement made on 30 June 2025 by Oncoinvent ASA (“Oncoinvent”) and BerGenBio ASA (“BerGenBio”) regarding the contemplated combination of the two companies through a statutory merger (the “Merger”). An extraordinary general meeting (the “EGM”) in Oncoinvent was held today at 12:00 hours (Oslo time). All proposals on the agenda were approved with the requisite majority, including the merger plan for the Merger dated 30 June 2025 (the “Merger Plan”).

Download

As separately announced by BerGenBio today, the merger and the contemplated rights issue have also been approved by an extraordinary general meeting of BerGenBio. As a consequence, the decision to approve the merger will now be filed with the Norwegian Register of Business Enterprises. Completion of the merger remains subject to customary terms and conditions, as further described in the Merger Plan.

The minutes of the EGM are attached hereto and made available on the Company’s website www.oncoinvent.com. For further information on the merger and the complete terms and conditions for the merger, please see the announcements of 30 June 2025, as well as the Merger Plan available on www.oncoinvent.com.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. Currently two phase 1/2a trials and one randomized phase 2 trial are ongoing in the US, UK and Europe. Preliminary clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The Oncoinvent team consists of approx. 30 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth Oslo.

About Radspherin

Radspherin® is an investigational radiopharmaceutical designed for the local treatment of cancer that has spread to body cavities. It consists of billions of calcium carbonate microparticles containing the radioactive material radium-224. The mode of action is the decay of radium-224 emitting alpha-particles, a highly potent form of ionizing radiation. Radspherin® is investigated in ongoing clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal cancer and it is administered intraperitoneally after surgical resection with removal of all macroscopic tumors.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Oncoinvent’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Oncoinvent’s expectations as of the date of this press release, and Oncoinvent disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

 

Øystein Soug, Chief Executive Officer

Email: soug@oncoinvent.com

 

Tore Kvam, Chief Financial Officer

Email: kvam@oncoinvent.com